SOL-GEL TECHNOLOGIES LTD (SLGL)
IL0011417206 - Common Stock
Overall SLGL gets a fundamental rating of 3 out of 10. We evaluated SLGL against 197 industry peers in the Pharmaceuticals industry. SLGL has a great financial health rating, but its profitability evaluates not so good. SLGL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SLGL has reported negative net income.
SLGL had a negative operating cash flow in the past year.
SLGL had negative earnings in 4 of the past 5 years.
In the past 5 years SLGL always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -60.14%, SLGL is not doing good in the industry: 63.59% of the companies in the same industry are doing better.
SLGL has a Return On Equity of -70.48%. This is comparable to the rest of the industry: SLGL outperforms 47.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.14% | ||
| ROE | -70.48% | ||
| ROIC | N/A |
ROA(3y)-29.16%
ROA(5y)-35.43%
ROE(3y)-33.35%
ROE(5y)-40.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SLGL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SLGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SLGL has been increased compared to 1 year ago.
The number of shares outstanding for SLGL has been increased compared to 5 years ago.
SLGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -6.05, we must say that SLGL is in the distress zone and has some risk of bankruptcy.
SLGL has a Altman-Z score of -6.05. This is in the lower half of the industry: SLGL underperforms 68.72% of its industry peers.
There is no outstanding debt for SLGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.05 |
ROIC/WACCN/A
WACC9.01%
2.3 Liquidity
A Current Ratio of 9.10 indicates that SLGL has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.10, SLGL belongs to the best of the industry, outperforming 84.62% of the companies in the same industry.
A Quick Ratio of 9.10 indicates that SLGL has no problem at all paying its short term obligations.
SLGL has a Quick ratio of 9.10. This is amongst the best in the industry. SLGL outperforms 84.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.1 | ||
| Quick Ratio | 9.1 |
3. Growth
3.1 Past
SLGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.91%.
The Revenue for SLGL has decreased by -60.05% in the past year. This is quite bad
Measured over the past years, SLGL shows a very strong growth in Revenue. The Revenue has been growing by 64.25% on average per year.
EPS 1Y (TTM)-54.91%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q32%
Revenue 1Y (TTM)-60.05%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Revenue growth Q2Q347%
3.2 Future
The Earnings Per Share is expected to grow by 22.22% on average over the next years. This is a very strong growth
Based on estimates for the next years, SLGL will show a very strong growth in Revenue. The Revenue will grow by 115.50% on average per year.
EPS Next Y29.31%
EPS Next 2Y25.93%
EPS Next 3Y19.28%
EPS Next 5Y22.22%
Revenue Next Year75.11%
Revenue Next 2Y110.97%
Revenue Next 3Y80.8%
Revenue Next 5Y115.5%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SLGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLGL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SLGL's earnings are expected to grow with 19.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.93%
EPS Next 3Y19.28%
5. Dividend
5.1 Amount
No dividends for SLGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SOL-GEL TECHNOLOGIES LTD
NASDAQ:SLGL (5/17/2024, 7:26:37 PM)
0.75
+0.01 (+1.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap20.89M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.14% | ||
| ROE | -70.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.1 | ||
| Quick Ratio | 9.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-54.91%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y29.31%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-60.05%
Revenue growth 3Y-43.83%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y